Advanced search
Publication Cover
Current Medical Research and Opinion Volume 25, 2009 - Issue 12
Submit an article Journal homepage
901
Views
116
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain

Richard L. Rauck Wake Forest University Health Sciences, Carolinas Pain Institute Center for Clinical Research, Winston Salem, NC, USACorrespondence[email protected] [email protected]
,
Marvin Tark Medical Director, Drug Studies America, Marietta, GA, USA
,
Eva Reyes Compassionate Cancer Care, Corona, CA, USA
,
Teresa G. Hayes Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA
,
Anthony J. Bartkowiak Director of Clinical Research, Blair Medical Associates, Altoona, PA, US
,
David Hassman Comprehensive Clinical Research, Berlin, NJ, USA
,
Srinivas Nalamachu International Clinical Research Institute, Overland Park, KS, USA
,
Rob Derrick Clinical Development, ProStrakan Inc, Bedminster, NJ, USA
&
Julian Howell Clinical Development, ProStrakan Inc, Bedminster, NJ, USA
 show all
Pages 2877-2885 | Accepted 28 Sep 2009, Published online: 08 Oct 2009

References

  • Portenoy RK, Hagen NA Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
  • Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83
  • Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
  • Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part I – assessment. Pharmacol Ther 2005;30:296-301
  • Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part II – management. Pharmacol Ther 2005;30:354-61
  • Simmonds MA Management of breakthrough pain due to cancer. Oncology (Williston Park) 1999;13:1103-8
  • Actiq® SPC. (Date of revision: January 2008). Cephalon Ltd, Hertfordshire, UK
  • Bredenberg S, Duberg M, Lennernas B, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003;20:327-34
  • Shojaei AH Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998;1:15-30
  • Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005;59:249-53
  • Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomised phase II study. Palliat Med 2009: in press
  • Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
  • Data on file. 2004. Study SuF-002
  • Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30
  • Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11
  • Rauck R, Derrick R, Howell J. Efficacy and tolerability of sublingual fentanyl in opioid-tolerant cancer patients with breakthrough pain: interim findings from two long-term, Phase III multi-centre studies. Pain Pract 2009;9(s1):93-168

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.